Both in Pharmaceuticals
Gyre Therapeutics vs Evolus
Over the past year GYRE returned −39.6% and EOLS returned +18.6%; their daily moves had a correlation of 0.21.
GYRE −39.6% EOLS +18.6%Growth of $1, one year, split-adjusted
| Metric | GYRE | EOLS |
|---|---|---|
| Price | $4.45 | $7.58 |
| Market cap | $471.3M | $500.7M |
| Today | +0.11% | +2.85% |
| 1 month | −37.2% | +2.7% |
| 6 months | −44.7% | +19.9% |
| Year to date | −37.0% | +14.0% |
| 1 year | −39.6% | +18.6% |
| Revenue growth (YoY) | −2.1% | +21.2% |
| Gross margin | 92.4% | 68.0% |
| Net margin | −40.1% | −9.6% |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | 1.6× |
| Net cash | $74.8M | -$141.9M |
| Dividend yield | — | — |
| Volatility (60d) | 88.3% | 49.2% |
| Short % of float | 11.5% | 12.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).